Reviewed listing: NASDAQ:ANIP · Analysis dated Oct 22, 2026
The underlying information has changed since this analysis. This earlier assessment has not yet been updated for those changes. It refers to the analysis date and original reviewed price shown here.
How does the company make money?
ANI sells specialty pharmaceuticals, generics, and established branded products. Key growth drivers include Cortrophin Gel for various inflammatory conditions and the ILUVIEN ocular implant.
What supports the business?
In the first half, revenue increased to 503.506 million USD from 408.493 million USD. Cortrophin Gel grew to 192.245 million USD. However, some total revenue and cash inflow came from one-time license components.
What could improve?
Further growth in Cortrophin sales, improved utilization, and debt reduction could increase earnings per share. ANI does not need to undertake the full development of a new, as-yet unapproved key product to achieve this.
How is the stock price assessed?
This assessment refers to the analysis and its quoted price shown here. It is not a live quote or a personal recommendation to buy.
72.24 USD are significantly above the midpoint of the model value, approximately 54 USD. After adjusting for one-time licensing components and deducting required debt repayment, this assumes 100 million USD in sustainable annual shareholder cash flow and 24 million shares. The price requires more growth than the cautious normalization supports.
What is the main risk?
High dependence on individual products, reimbursement rules and suppliers remains. In addition, substantial loans and a convertible bond offset the cash balance; stock-based compensation and new acquisitions could reduce the benefit of growth.
What is the overall assessment?
ANI is growing and generating operating cash flow. However, one-time licensing payments, required debt repayment, and stock-based compensation reduce the sustainable surplus available. At 72.24 USD, the share price is well above the cautious model midpoint of about 54 USD; there is currently no established price opportunity.
Continue exploring this stock in your account
A free Marqora account gives you the detailed analysis with further evidence and lets you compare and save stocks. Your selected stock is kept when you sign in or register.
Open the full analysis in a free account →
Already have an account? Sign in